295 related articles for article (PubMed ID: 22495546)
21. Risk factors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia.
Liu CP; Shih SC; Wang NY; Wu AY; Sun FJ; Chow SF; Chen TL; Yan TR
J Microbiol Immunol Infect; 2016 Dec; 49(6):934-940. PubMed ID: 25553994
[TBL] [Abstract][Full Text] [Related]
22. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia.
Lee NY; Lee HC; Ko NY; Chang CM; Shih HI; Wu CJ; Ko WC
Infect Control Hosp Epidemiol; 2007 Jun; 28(6):713-9. PubMed ID: 17520546
[TBL] [Abstract][Full Text] [Related]
23. Risk factors and outcome analysis of acinetobacter baumannii complex bacteremia in critical patients.
Lee HY; Chen CL; Wu SR; Huang CW; Chiu CH
Crit Care Med; 2014 May; 42(5):1081-8. PubMed ID: 24394630
[TBL] [Abstract][Full Text] [Related]
24. Prediction of patient outcome from Acinetobacter baumannii bacteremia with Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation (APACHE) II scores.
Chen SJ; Chao TF; Chiang MC; Kuo SC; Chen LY; Yin T; Chen TL; Fung CP
Intern Med; 2011; 50(8):871-7. PubMed ID: 21498935
[TBL] [Abstract][Full Text] [Related]
25. Factors influencing survival in patients with multi-drug-resistant Acinetobacter bacteraemia.
Metan G; Sariguzel F; Sumerkan B
Eur J Intern Med; 2009 Sep; 20(5):540-4. PubMed ID: 19712862
[TBL] [Abstract][Full Text] [Related]
26. Clinical characteristics and predictors of mortality in patients with Enterobacter aerogenes bacteremia.
Chang EP; Chiang DH; Lin ML; Chen TL; Wang FD; Liu CY
J Microbiol Immunol Infect; 2009 Aug; 42(4):329-35. PubMed ID: 19949757
[TBL] [Abstract][Full Text] [Related]
27. [Analysis of clinical manifestations and risk factors of mortality in Acinetobacter baumannii bloodstream infection].
Zhang Y; Zhou H; Cai H; Yang Q; Shen Q; Shen Y; Zhou J
Zhonghua Nei Ke Za Zhi; 2016 Feb; 55(2):121-6. PubMed ID: 26875581
[TBL] [Abstract][Full Text] [Related]
28. A multicenter case-case control study for risk factors and outcomes of extensively drug-resistant Acinetobacter baumannii bacteremia.
Ng TM; Teng CB; Lye DC; Apisarnthanarak A
Infect Control Hosp Epidemiol; 2014 Jan; 35(1):49-55. PubMed ID: 24334798
[TBL] [Abstract][Full Text] [Related]
29. The clinical implication and prognostic predictors of tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii.
Ye JJ; Lin HS; Kuo AJ; Leu HS; Chiang PC; Huang CT; Lee MH
J Infect; 2011 Nov; 63(5):351-61. PubMed ID: 21846481
[TBL] [Abstract][Full Text] [Related]
30. Mortality attributable to carbapenem-resistant nosocomial Acinetobacter baumannii infections in a Turkish university hospital.
Aydemir H; Celebi G; Piskin N; Oztoprak N; Keskin AS; Aktas E; Sumbuloglu V; Akduman D
Jpn J Infect Dis; 2012; 65(1):66-71. PubMed ID: 22274161
[TBL] [Abstract][Full Text] [Related]
31. Comparison between bacteremia caused by Acinetobacter pittii and Acinetobacter nosocomialis.
Liu YM; Lee YT; Kuo SC; Chen TL; Liu CP; Liu CE
J Microbiol Immunol Infect; 2017 Feb; 50(1):62-67. PubMed ID: 25735795
[TBL] [Abstract][Full Text] [Related]
32. Risk factors for 30-day mortality in patients with carbapenem-resistant Acinetobacter baumannii during an outbreak in an intensive care unit.
Prates CG; Martins AF; Superti SV; Lopes FS; Ramos F; Cantarelli VV; Zavascki AP
Epidemiol Infect; 2011 Mar; 139(3):411-8. PubMed ID: 20513254
[TBL] [Abstract][Full Text] [Related]
33. Genotypic analysis of Acinetobacter bloodstream infection isolates in a Turkish university hospital.
Alp E; Esel D; Yildiz O; Voss A; Melchers W; Doganay M
Scand J Infect Dis; 2006; 38(5):335-40. PubMed ID: 16709534
[TBL] [Abstract][Full Text] [Related]
34. Multidrug Resistance Acinetobacter Bacteremia Secondary to Ventilator-Associated Pneumonia: Risk Factors and Outcome.
Brotfain E; Borer A; Koyfman L; Saidel-Odes L; Frenkel A; Gruenbaum SE; Rosenzweig V; Zlotnik A; Klein M
J Intensive Care Med; 2017 Oct; 32(9):528-534. PubMed ID: 26902255
[TBL] [Abstract][Full Text] [Related]
35. Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia.
Zheng YL; Wan YF; Zhou LY; Ye ML; Liu S; Xu CQ; He YQ; Chen JH
Am J Infect Control; 2013 Jul; 41(7):e59-63. PubMed ID: 23523521
[TBL] [Abstract][Full Text] [Related]
36. Acinetobacter baumannii bacteraemia in patients with haematological malignancy: a multicentre retrospective study from the Infection Working Party of Jiangsu Society of Hematology.
Wang X; Zhang L; Sun A; Yang X; Sang W; Jiang Y; Cheng J; Wang J; Zhou M; Chen B; Ouyang J
Eur J Clin Microbiol Infect Dis; 2017 Jul; 36(7):1073-1081. PubMed ID: 28101785
[TBL] [Abstract][Full Text] [Related]
37. Attributable mortality of imipenem-resistant nosocomial Acinetobacter baumannii bloodstream infection.
Jamulitrat S; Arunpan P; Phainuphong P
J Med Assoc Thai; 2009 Mar; 92(3):413-9. PubMed ID: 19301737
[TBL] [Abstract][Full Text] [Related]
38. Using the rate of bacterial clearance determined by real-time polymerase chain reaction as a timely surrogate marker to evaluate the appropriateness of antibiotic usage in critical patients with Acinetobacter baumannii bacteremia.
Chuang YC; Chang SC; Wang WK
Crit Care Med; 2012 Aug; 40(8):2273-80. PubMed ID: 22809902
[TBL] [Abstract][Full Text] [Related]
39. Clinical predictors of Pseudomonas aeruginosa or Acinetobacter baumannii bacteremia in patients admitted to the ED.
Kang CI; Chung DR; Peck KR; Song JH;
Am J Emerg Med; 2012 Sep; 30(7):1169-75. PubMed ID: 22030178
[TBL] [Abstract][Full Text] [Related]
40. [Factors associated with mortality in Acinetobacter baumannii infected intensive care unit patients].
Karabay O; Yahyaoğlu M; Oğütlü A; Sandıkçı O; Tuna N; Ceylan S
Mikrobiyol Bul; 2012 Apr; 46(2):335-7. PubMed ID: 22639324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
